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Edited by Sandro SonninoAbstract Sphingosine-1-phosophate, generated from the phos-
phorylation of sphingosine by sphingosine kinase enzymes, is
suggested to function as an intracellular second messenger for
inﬂammatory mediators, including formyl peptide, C5a, and
Fc. More recently, a role for sphingosine kinases during inﬂam-
mation has also been proposed. Here we show that sphingosine
kinase 1 knockout mice exhibit normal inﬂammatory cell
recruitment during thioglycollate-induced peritonitis and that
sphingosine kinase 1-null neutrophils respond normally to formyl
peptide. In the collagen-induced arthritis model of rheumatoid
arthritis, sphingosine kinase 1 knockout mice developed arthritis
with normal incidence and severity. Our ﬁndings show that
sphingosine kinase 1 is dispensable for inﬂammatory responses
and support the need for more extensive studies of sphingosine
kinases in inﬂammation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Arthritis1. Introduction
The lysophospholipid sphingosine-1-phosophate (S1P) acts
as an extracellular ligand at S1P receptors to regulate diverse
physiologic functions, including angiogenesis, lymphocyte
recirculation, vascular permeability, and heart rate [1–3]. S1P
is also suggested to function as an intracellular second messen-
ger in mobilizing calcium, promoting cell proliferation and sur-
vival [4]. In addition, S1P is a critical intermediate in
sphingolipid and glycero-phospholipid metabolism. It is gener-
ated from the phosphorylation of sphingosine by sphingosine
kinase enzymes (Sphk1 and Sphk2) and is degraded by S1P
phosphatases (Spp1 and Spp2) and S1P lyase (SPL). Thus,
Sphks are fundamental to regulating S1P levels and its intra-
cellular roles.Abbreviations: S1P, Sphingosine-1-phosophate; Sphk1, Sphingosine
kinase 1; Spp, Sphingosine-1-phosphate phosphatase; SPL, Sphingo-
sine-1-phosphate lyase; CIA, Collagen-induced arthritis
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doi:10.1016/j.febslet.2006.07.035Recently, the role of Sphk in immunity and inﬂammation
has been the focus of intense study. In mast cells, macro-
phages, and neutrophils, Sphk activity is stimulated by the
ligation of plasma membrane receptors for C5a, Fc and formyl
peptide (fMLP) [5–8]. Inhibition of Sphk activity and anti-
sense knockdown of Sphk1 inhibited C5a-stimulated Ca2+
mobilization, enzyme release, and chemotaxis in both neutro-
phils and macrophages [7,8]. In addition, experimental models
using pharmacologic inhibitors support a role for Sphk in
acute inﬂammatory states. Pretreatment of mice with a Sphk
inhibitor, dimethylsphingosine (DMS), prevented C5a-induced
peritonitis [9]. However, DMS is known to have non-speciﬁc,
oﬀ-target eﬀects [10,11]. Inhibition of Sphk was also shown
to prevent neutrophil activation and lung permeability in a
model of trauma and hemorrhagic shock [12]. To date, the ef-
fects of Sphk inhibition on inﬂammation have been attributed
to intracellular S1P-mediated signaling, Thus, previous work
suggests a role for Sphk during inﬂammation, although the sig-
niﬁcance in vivo remains unclear.
In this study, we sought to determine if Sphk1 is essential
during inﬂammation using Sphk1 knockout mice [13]. We
examined the requirement for Sphk1 in the acute inﬂammatory
responses that occur in thioglycollate-induced peritonitis. We
also analyzed the function of Sphk1 during chronic inﬂamma-
tion using the collagen-induced arthritis (CIA) model of
rheumatoid arthritis (RA), which shares clinical, immunologi-
cal, and histological features with the human disease of RA
[14].2. Materials and methods
2.1. Mice
Sphk1 null mice (Sphk1/) were generated and genotyped as de-
scribed [13]. For neutrophil and peritonitis experiments, mice were
backcrossed ﬁve generations to C57BL/6 (Jackson Laboratory). All
mice were housed under speciﬁc pathogen-free conditions. Animal care
and experimental procedures were approved by the University of Con-
necticut Animal Care Committee.
2.2. Thioglycollate-induced peritonitis
8–12 week-old male Sphk1/ and Sphk1+/+ mice were injected
intraperitoneally (IP) with 2 ml sterile thioglycollate (TG) (3% wt/
vol). Four hours after challenge, mice were lavaged with 5 ml cold
Hanks buﬀered saline (HBSS, Invitrogen). Total leukocyte counts were
determined using a Coulter counter (Beckman Coulter) and manual
leukocyte diﬀerentials were counted from three high-power ﬁelds of
May-Grunwald Giemsa (Sigma) stained cytospin preparations.blished by Elsevier B.V. All rights reserved.
Fig. 1. Sphk1/mice develop peritonitis in response to TG. Sphk1+/+
and Sphk1/ mice (n = 9 per group) were injected i.p. with TG and
4 h later cells were collected by peritoneal lavage. (A) Total cell
number and (B) leukocyte composition of cells recruited to the
peritoneum. Data shown are the means ± S.E. No statistically signif-
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Thioglycollate-elicited neutrophils were isolated by peritoneal lavage
with 5 ml cold HBSS four hours after I.P. challenge with 2 ml thiogly-
collate (3% wt/vol). Cells were P 80% neutrophils by May-Grunwald
Giemsa staining, and >95% viable by trypan blue exclusion. N-formyl-
Met-Leu-Phe (fMLP) (Sigma) was dissolved in DMSO and stored as
single-use aliquots at 80 C. NADPH oxidase activity was measured
using superoxide dismutase-inhibitable isoluminol chemiluminescence
[15]. 5 · 105 cells were suspended in 50 lM isoluminol (Sigma), 5 U/
ml horseradish peroxidase (MP Biomedical), in phosphate buﬀered sal-
ine with 0.5 mM CaCl2, 0.5 mM MgCl2, and 7.5 mM D-glucose
(PBSG). Cell suspensions were added to a 96 well plate, stimulated
with 1 lM fMLP or PBSG, and read on a luminescence plate reader
over 5 min. For immunoblot analyses, 2 · 106 neutrophils in PBSG
were stimulated with 1 lM fMLP at 37 C for indicated times, lysed
in 6· sample buﬀer (at 1·: 50 mM Tris, pH 7.5, 1.5% SDS, 0.2% deoxy-
cholate, 0.2% Triton X-100, 10 mMMgCl2), and DNA was sheared by
passing through a 25G needle 5–10 times. Equal amounts of protein
were separated by 10% SDS/PAGE and blotted onto a nitrocellulose
membrane. Immunoblot analyses were performed using phospho-spe-
ciﬁc antibodies for ERK p42/44, p38, AKT (Cell Signaling) and aPAK
(SantaCruz). mRNA expression analysis, RNA extraction, cDNA syn-
thesis and real-time PCR analysis were performed as described [16].
Brieﬂy, total RNA was extracted from elicited neutrophils using
RNA-STAT-60 (Tel-Test) following manufacturer’s instructions.
RNA was treated with DNase I, followed by reverse transcription.
Equal amounts of cDNA were run in duplicate SYBR green PCRs
using an ABI 7900HT sequence detection system (Applied Biosys-
tems). Primer sets for PCR were Sphk1 (5 0-GGAGGAGGCAGAG-
ATAACCTT-3 0, 5 0-GACCCAACTCCTCTGCACACA-3 0), Sphk2
(5 0-GCCCGAGATGGTCTAGTCT-30, 5 0-GTGGGTAGGTGTA-
GATGCAGA-3 0), Spp1 (5 0-GGGTGCTGGTCATGTACCTG-3 0,
5 0-CCCGTAGATAAGAGGATACTGCC-3 0), Spp2 (5 0-GTTCTC
TACGCTGGTGTGTCT-3 0, 5 0-GCAGGGTAGGTGAGAGCAAT-
3 0), SPL (5 0-CCTGTGTACTCTGCTGATAGTCT-3 0, 5 0-CTGTTG-
TTCGATCTTACGTCCA-3 0), b-actin (5 0-GACAGGATGCAGA-
AGGAGATTACT-3 0, 5 0-TGATCCACATCTGCTGGAAGGT-3 0).
Data were analyzed to account for reaction eﬃciency [17] and results
expressed relative to b-actin expression.icant diﬀerences were observed in (A) (P = 0.234), or (B).
Fig. 2. fMLP-induced NADPH oxidase activity and fMLP receptor signaling does not require Sphk1. (A) Superoxide generation by Sphk1+/+ and
Sphk1/ neutrophils stimulated with 1lM fMLP. Results are represented in relative light units (RLU). (B) Kinase phosphorylation in Sphk1+/+
and Sphk1/ neutrophils stimulated with 1 lM fMLP. (C) Neutrophil Sphk1 and Sphk2 mRNA levels. (D) Neutrophil Spp1, Spp2 and SPL
mRNA levels. Data shown are the means ± S.D. of at least two independent experiments.
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Sphk1mice were backcrossed 6 generations to DBA/1 mice (Jackson
Laboratory). CIA was induced on day 1 in 6–7 week-old male Sphk1/
 and Sphk1+/+ mice by intradermal tail base injection of 100 lg bo-
vine collagen II (CII) supplemented with 2.0 mg/ml M. tuberculosis
(Chondrex) emulsiﬁed in complete Freund’s adjuvant (CFA) [18]. On
day 21, mice received an intradermal tail base injection of 100 lg
CII in incomplete Freund’s adjuvant. Clinical severity of disease was
evaluated by a blinded examiner every 4 days [19]. Each paw was
scored for inﬂammation on a scale of 0–4: 0, normal; 1, erythema
and mild swelling conﬁned to ankle, or tarsals, or individual digits;
2, moderate erythema and swelling of tarsals and ankle; 3, severe ery-
thema and mild swelling of ankle, tarsals and digits; 4, severe erythema
and severe swelling of ankle, tarsals and digits. Total daily scores for
each mouse were obtained by adding scores from all four paws. On
day 60 mice were euthanized and forepaws were weighed. For histol-
ogy, paws were ﬁxed with 10% formalin, decalciﬁed in Decal (Fisher),
embedded in paraﬃn, and 5 lm sections were stained with hematoxi-
lin/eosin.
2.5. Measurement of S1P levels
Peritoneal exudates were collected, centrifuged at 500 · g for 5 min,
and supernatants stored at 80C. For determining S1P levels during
arthritis, paws were severed at the wrist joint and tissues digested with
0.4 mg proteinase K in 0.3 ml of 1 mM Tris, pH 8.5, at 60 C for 2 h,
sonicated on ice, centrifuged, and supernatants stored at 80 C. S1P
levels were analyzed by HPLC with a ﬂuorescent detection system (Shi-
madzu) after lipid extraction and derivatization with o-phthalaldehyde
as previously described [20].
2.6. Data analysis
Results are representative of at least three independent experiments.
Statistical signiﬁcance was determined by unpaired Student’s t test
using P < 0.05 as signiﬁcant.Fig. 3. Sphk1/ mice are fully susceptible to collagen-induced
arthritis. Sphk1+/+ (n = 8) and Sphk1/ mice (n = 14) in the DBA/
1 background were immunized with bovine CII on days 1 and 21.
Beginning on day 21, individual paws were scored for inﬂammation on
a scale of 0–4 as described in Section 2. (A) Arthritis severity measured
by clinical score. (B) Arthritis incidence and paw edema (inset)
measured as percentage of mice with arthritis and forepaw weight at
day 60, respectively.3. Results
3.1. Sphk1 knockout mice exhibit normal inﬂammatory cell
recruitment
Acute inﬂammation is characterized by the rapid recruit-
ment of leukocytes from the periphery to the site of inﬂamma-
tion. To analyze the role of Sphk1 in acute inﬂammation,
peritonitis was induced in Sphk1/ and Sphk1+/+ mice by
thioglycollate injection [21]. In both Sphk1/ and Sphk1+/+
mice, inﬂammatory cells were recruited into the peritoneum
at 4 h post-injection (Fig. 1A), and maintained equivalent cell
numbers through at least 48 h (data not shown). There was no
signiﬁcant diﬀerence in the composition of cells (as determined
by diﬀerential cell counts) obtained from Sphk1/ and
Sphk1+/+ mice, with granulocytes being predominant in both
(Fig. 1B). Sphk1/ mice show a greater than 50% reduction
in serum S1P levels, but relatively equivalent S1P levels in
other tissues [13]. Similarly, peritoneal exudates in Sphk1/
and Sphk1+/+ mice with thioglycollate-induced peritonitis
contained low levels of S1P (19–20 nM), with no signiﬁcant
diﬀerences between wild-type and Sphk1/ groups. This
suggests that tissue S1P levels at the inﬂammatory site are
low compared to plasma levels (400 nM) and that local
action of Sphk2 is suﬃcient to compensate for the lack of
Sphk1.
3.2. NADPH oxidase activity and fMLP signaling
Neutrophils are often the primary cell type recruited during
acute inﬂammation. Once activated, they display a variety of
microbicidal responses including phagokinetic activity and
superoxide generation. We therefore examined the ability ofSphk1/ and Sphk1+/+ neutrophils to produce superoxide.
No diﬀerence in superoxide production in response to fMLP
was evident in neutrophils lacking Sphk1 (Fig. 2A). To con-
ﬁrm that fMLP-induced signaling was normal in Sphk1/
neutrophils, we determined the activation levels of several ki-
nases downstream from the fMLP receptor. As shown in
Fig. 2B, fMLP induced equivalent phosphorylation of p38
mitogen-activated kinase (p38), p44/42 mitogen-activated ki-
nase (ERK), protein kinase B (Akt), and p21-activated kinase
(PAK) in Sphk1/ and Sphk1+/+ neutrophils.
3.3. Sphk expression levels in Sphk1/ neutrophils
In order to rule out possible upregulation of Sphk2 in
Sphk1/ mice, we determined the mRNA levels of both
known Sphk isoforms using real-time PCR. Sphk2 mRNA lev-
els were not elevated in Sphk1/ neutrophils, which as ex-
pected, lacked Sphk1 mRNA (Fig. 2C). In addition, mRNA
levels of other S1P-metabolizing enzymes, including S1P phos-
phatases (Spp1 and Spp2) and S1P lyase (SPL) were not al-
tered in Sphk1/ neutrophils (Fig. 2D). The absence of
compensatory Sphk2 upregulation in Sphk1/mice is consis-
tent with previous studies [13].
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Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by chronic synovitis. Recently, Sphk1
was proposed as a regulator of B cell apoptosis in RA
[22]. We assessed the possible involvement of Sphk1 in RA
using the murine CIA model[18]. This well established model
induces T-cell dependent autoimmunity, resulting in chronic
synovitis and joint destruction [23]. Loss of Sphk1 did not
aﬀect the development or progression of CIA, as Sphk1/
and Sphk1+/+ mice developed severe joint inﬂammation of
the hind and forepaws, as assessed by clinical scores
(Fig. 3A). The incidence of CIA in both groups reached
100% 40 d after immunization, with >2 fold increase in fore-
paw weight on day 60 (Fig. 3B). Histopathologic analysis
conﬁrmed the development of CIA. 60 d after immunization,
Sphk1/ and Sphk1+/+ mice exhibited CIA-characteristic
chronic synovial inﬂammation, pannus formation and carti-
lage destruction (Fig. 4). Tissue levels of S1P were also mea-
sured. S1P levels in forepaws of naive Sphk1/ and
Sphk1+/+ mice were 5.5 ± 0.4 and 3.9 ± 0.5 pmol/mg protein.
No change in S1P levels were seen with the induction of CIA
(5.2 ± 1.3 and 4.9 ± 0.7 pmol/mg protein, Sphk1/ and
Sphk1+/+, respectively). This suggests that compensation by
the Sphk2 enzyme occurred in the inﬂamed joints of
Sphk1/ mice.Fig. 4. Representative joint histopathology from Sphk1+/+ and Sphk1/ m
(B) mice with even joint spaces (js), 10·magniﬁcation. (C,D) Aﬀected joints fr
destruction (cd), intra-articular exudates (ie) and synovial hyperplasia (sh), 24. Discussion
Sphk1 has been suggested to function as a second messen-
ger in a variety of immune cells, including neutrophils, mast
cells, and macrophages [5–8]. In vivo studies with pharmaco-
logic Sphk inhibitors further support a role for Sphks in im-
mune cell function [9,12]. With these observations in mind, we
expected that mice lacking Sphk1 would have defective
inﬂammatory responses. In this study we have shown that
Sphk1 is not required for inﬂammatory cell recruitment dur-
ing thioglycollate-induced peritonitis. Compared to wild-type
controls, Sphk1/ mice were able to recruit equivalent num-
bers of neutrophils and monocytes/macrophages to the perito-
neal cavity. This suggests that the overall inﬂammatory
cascade and resulting migratory response of leukocytes were
not signiﬁcantly altered by the absence of Sphk1. We have
also shown that Sphk1 null neutrophils generate large
amounts of superoxide in response to fMLP, and that kinase
signaling events downstream of the fMLP receptor remain in-
tact. Although we cannot rule out signaling functions of
Sphk1 during the action of proinﬂammatory ligands other
than fMLP, there is no gross deﬁcit during acute inﬂamma-
tion in the Sphk1 knockout mouse.
Sphk1 null mice were also able to develop chronic inﬂamma-
tion, showing prominent joint destruction in the CIA model ofice. (A,B) Normal joints from untreated Sphk1+/+ (A) and Sphk1/
om Sphk1+/+ (C) and Sphk1/ (D) mice on day 60 showing cartilage
0· magniﬁcation.
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anti-CII antibodies and adaptive immunity [24]. T and B cells
are critical for disease initiation, with other inﬂammatory cells
recruited to aﬀected joints. Thus, the ability of Sphk1 knock-
out mice to develop CIA suggests that T and B cells do not rely
on Sphk1 in order to function normally in generating adaptive
immune responses.
S1P function as an inﬂammatory mediator in the extracellu-
lar milieu is an attractive idea that draws parallels to prosta-
noids and other lipid mediators. Although blood contains
large stores of S1P, tissue levels are generally much lower;
which is likely the result of increased degradation. Indeed,
we failed to detect any increase in tissue S1P levels during
acute or chronic inﬂammatory states. This questions the role
of S1P as an inﬂammatory mediator, but does not negate pos-
sible micro-environment or intracellular functions.
To fully understand our results, it is important to distinguish
our study, using Sphk1 knockout mice, with others using phar-
macological inhibitors. Most studies of Sphks to date have
used sphingolipids to competitively inhibit Sphk activity
[5,7,9]. Such inhibitors, including dihydrosphingosine (DHS)
and dimethylsphingosine (DMS), are known to inhibit protein
kinase C (PKC) as well [10,11]. Indeed, their properties as neu-
trophil inhibitors have been attributed to PKC inhibition [25–
28]. Thus when using sphingolipid inhibitors it is diﬃcult to
separate eﬀects on PKC from those on Sphk. In addition,
sphingosine and derivatives also profoundly alter ion channel
activity [29].The exception may be the Sphk inhibitor SKI-2,
whose speciﬁcity for Sphk is purportedly higher [30]. More-
over, all of the current Sphk inhibitors are isoform-non-spe-
ciﬁc, i.e. inhibiting both Sphk1 and Sphk2.
In contrast, by disrupting the Sphk1 gene we have in eﬀect
wholly and singly inhibited the Sphk1 enzyme. Although pre-
vious studies have targeted Sphk1 with antisense knockdown
[7,8,31], the eﬀects of long-term and global loss of Sphk1 re-
main unknown. To this end, we have conﬁrmed that Sphk2
is not upregulated after the loss of Sphk1 [13]. These data show
that Sphk1 activity is dispensible for inﬂammatory responses
under the conditions examined here. This suggests that the
functions of Sphk1 and Sphk2 may be redundant. Alterna-
tively, it is possible that mice lacking the Sphk1 gene during
embryonic development may be adapted to not rely on this
pathway for inﬂammatory responses postnatally. Thus, acute
inhibition of Sphk in normal animals may well lead to modu-
lation of inﬂammatory responses. However, the normal pheno-
type of Sphk1 null mice during acute and chronic
inﬂammation supports the need for more extensive studies of
Sphks in immune function.
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